Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

HERTHENA-Lung01: Patritumab Deruxtecan in Advanced EGFR-Mutated NSCLC

October 26th 2023

Experts on lung cancer review key data from the HERTHENA-Lung01 study investigating patritumab deruxtecan (HER3-DXd) in patients with advanced EGFR-mutated NSCLC.

The Role of HER3 in Non–Small Cell Lung Cancer

October 26th 2023

A medical oncologist discusses the role of HER3 in the treatment of non–small cell lung cancer and provides an overview of the HERTHENA-Lung01 clinical trial.

Breaking Ground in Breast, Lung, Gynecologic, and Gastrointestinal Cancers From ESMO 2023: Drs Tarantino, Sands, Vergote, and Janjigian

October 24th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Amivantamab With or Without Lazertinib Extends PFS in EGFR+ Advanced NSCLC After Progression on Osimertinib

October 23rd 2023

Patients with EGFR-mutated advanced non–small cell lung cancer who experienced disease progression after treatment with osimertinib experienced a progression-free survival benefit with amivantamab plus chemotherapy with or without lazertinib compared with chemotherapy alone.

Dato-DXd Significantly Improves PFS in Select Subsets of Advanced/Metastatic NSCLC

October 23rd 2023

The Trop-2 directed antibody drug conjugate datopotamab deruxtecan demonstrated a statistically significant improvement in progression-free survival vs docetaxel in patients with advanced or metastatic non–small cell lung cancer, however those with squamous histology did not experience a benefit.

Frontline Amivantamab Plus Lazertinib Bests Osimertinib in Advanced EGFR+ NSCLC

October 23rd 2023

The combination of amivantamab and lazertinib reduced the risk of disease progression or death by 30% compared with osimertinib alone as frontline therapy for patients with advanced non–small cell lung cancer harboring classical EGFR sensitizing mutations.

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023

Dr Keshava discusses the rationale behind lung nodule programs, common barriers to implementing these programs, and how multidisciplinary collaboration can lead to successful early lung cancer diagnoses.

Dr Cho on First-Line Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC

October 23rd 2023

Byoung Chul Cho, MD, PhD, discusses key findings from the phase 3 MARIPOSA study of first-line amivantamab plus lazertinib vs osimertinib in EGFR-mutant locally advanced or metastatic non– small cell lung cancer.

Trastuzumab Deruxtecan Wins EU Approval for HER2-Mutated Advanced NSCLC

October 23rd 2023

The European Commission has approved fam-trastuzumab deruxtecan-nxki for the treatment of patients with advanced non–small cell lung cancer whose tumors harbor an activating HER2 mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.

Osimertinib Plus Chemo Improves CNS PFS in EGFR+ Advanced NSCLC With Baseline Brain Metastases

October 21st 2023

Osimertinib plus chemotherapy reduced the risk of central nervous system disease progression or death vs osimertinib alone in patients with locally advanced or metastatic EGFR-positive non–small cell lung cancer who had brain metastases at baseline, according to data from the phase 3 FLAURA2 trial.

Looking at Novel Treatments in Lung and Genitourinary Cancers From ESMO 2023: Drs Janne and Bastos

October 21st 2023

Dr Girard on the Efficacy of First-Line Amivantamab Plus Chemotherapy in EGFR Exon 20 Insertion+ NSCLC

October 21st 2023

Nicolas Girard, MD, PhD, discusses primary efficacy results from the phase 3 PAPILLON trial of amivantamab plus chemotherapy in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

Amivantamab Plus Chemotherapy Nearly Doubles PFS in EGFR Exon 20–Mutant NSCLC

October 21st 2023

The combination of amivantamab-vmjw (Rybrevant) and chemotherapy produced a median progression-free survival of 11.4 months vs 6.7 months with chemotherapy alone in patients with advanced, EGFR exon 20 insertion–positive non–small cell lung cancer.

Alectinib Elicits DFS Benefit in Early-Stage, Resected, ALK+ NSCLC

October 21st 2023

Treatment with the oral ALK inhibitor alectinib led to a statistically significant improvement in disease-free survival in patients with resected ALK-positive non–small cell lung cancer.

Perioperative Nivolumab Significantly Improves EFS in Previously Untreated Resectable NSCLC

October 21st 2023

Neoadjuvant treatment with nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab resulted in a statistically significant improvement in event-free survival vs placebo plus chemotherapy, in patients with previously untreated resectable stage II to IIIB non-small cell lung cancer, according to data from the phase 3 CheckMate 77T trial.

Selpercatinib Significantly Improves PFS Vs Chemo With or Without Pembrolizumab in RET+ NSCLC

October 21st 2023

Selpercatinib (Retevmo) showcased superior efficacy, with improved progression-free survival, vs chemotherapy with or without pembrolizumab in the first-line treatment of patients with RET fusion–positive non–small cell lung cancer.

Second-Line Sacituzumab Govitecan Elicits Responses, Provides Disease Control in ES-SCLC

October 21st 2023

Second-line treatment with sacituzumab govitecan-hziy led to responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.

Dostarlimab Plus Chemo Continues to Demonstrate Strong Clinical Efficacy in Advanced NSCLC

October 20th 2023

Dostarlimab plus chemotherapy elicited a higher objective response rate and showcased a numerical improvement in overall survival compared with pembrolizumab and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.

Pembrolizumab Plus Adagrasib Demonstrates Preliminary Efficacy in KRAS G12C–Mutated NSCLC

October 20th 2023

Concurrent adagrasib and pembrolizumab generated early signals of efficacy in patients with treatment-naïve, advanced non–small cell lung cancer harboring KRAS G12C mutations, particularly in those who had a PD-L1 tumor proportion score of at least 50%.

Tarlatamab Demonstrates Antitumor Activity With Durable Responses in Previously Treated SCLC

October 20th 2023

Treatment with the bispecific T-cell engager tarlatamab demonstrated antitumor activity and favorable safety outcomes in patients with previously treated small cell lung cancer.